Your browser doesn't support javascript.
loading
Second-line injectable drugs for rifampicin-resistant tuberculosis: better the devil we know?
Tahseen, Sabira; Van Deun, Armand; de Jong, Bouke C; Decroo, Tom.
Affiliation
  • Tahseen S; National TB Reference laboratory, National TB Control Program, Islamabad, Pakistan.
  • Van Deun A; Independent Consultant, 3000 Leuven, Belgium.
  • de Jong BC; Institute of Tropical Medicine, Unit of Mycobacteriology, Department of Biomedical Sciences, 2000, Antwerp, Belgium.
  • Decroo T; Institute of Tropical Medicine, Unit of HIV and TB, Department of Clinical Sciences, 2000, Antwerp, Belgium.
J Antimicrob Chemother ; 76(4): 831-835, 2021 03 12.
Article in En | MEDLINE | ID: mdl-33258921
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pharmaceutical Preparations / Tuberculosis, Multidrug-Resistant Type of study: Guideline Limits: Humans Language: En Journal: J Antimicrob Chemother Year: 2021 Type: Article Affiliation country: Pakistan
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pharmaceutical Preparations / Tuberculosis, Multidrug-Resistant Type of study: Guideline Limits: Humans Language: En Journal: J Antimicrob Chemother Year: 2021 Type: Article Affiliation country: Pakistan